Ryvu Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Ryvu Therapeutics has a total shareholder equity of PLN177.8M and total debt of PLN80.5M, which brings its debt-to-equity ratio to 45.3%. Its total assets and total liabilities are PLN403.2M and PLN225.4M respectively.
Key information
45.3%
Debt to equity ratio
zł80.52m
Debt
| Interest coverage ratio | n/a |
| Cash | zł247.55m |
| Equity | zł177.75m |
| Total liabilities | zł225.43m |
| Total assets | zł403.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9Y4's short term assets (PLN295.8M) exceed its short term liabilities (PLN97.5M).
Long Term Liabilities: 9Y4's short term assets (PLN295.8M) exceed its long term liabilities (PLN127.9M).
Debt to Equity History and Analysis
Debt Level: 9Y4 has more cash than its total debt.
Reducing Debt: 9Y4's debt to equity ratio has increased from 2% to 45.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9Y4 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 9Y4 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 8.3% each year.